WO2000061120A1 - Préparations destinées à être absorbées par voie percutanée - Google Patents
Préparations destinées à être absorbées par voie percutanée Download PDFInfo
- Publication number
- WO2000061120A1 WO2000061120A1 PCT/JP2000/002266 JP0002266W WO0061120A1 WO 2000061120 A1 WO2000061120 A1 WO 2000061120A1 JP 0002266 W JP0002266 W JP 0002266W WO 0061120 A1 WO0061120 A1 WO 0061120A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- salt
- acid
- organic acid
- comparative example
- hydrochloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Definitions
- the basic drug or a salt thereof, an organic acid or a salt thereof, and the solubility parameter are determined.
- the present invention relates to a percutaneous absorption preparation containing a liquid component in the range of 1 to 13 (cal / cm 3 ) 1/2 and having extremely excellent skin permeability of drugs.
- transdermal absorption enhancer for example, dimethylacetamide may be used as an absorption enhancer in combination with a lower alkylamide.
- dimethylacetamide may be used as an absorption enhancer in combination with a lower alkylamide.
- ethyl alcohol, isopropyl alcohol, isopropyl palmitate (US Pat. No. 3,472,931), 2-virolidone and suitable oils, esters of linear fatty acids and alcohols U.S. Pat. No. 4,017,
- a method combining a drug and an organic acid has been reported as a transdermal formulation.
- a tape formulation in which betamethasone valerate and an organic acid are combined with a natural rubber-based adhesive Japanese Patent Publication No. 63-45368
- non-steroids are used in an acrylic adhesive.
- Examples of tape preparations that combine organic anti-inflammatory analgesics and organic acids Japanese Patent Publication No. 7-44)
- non-steroid anti-inflammatory analgesic salts contain organic acids and glycols.
- a non-steroid anti-inflammatory analgesic having a salt form of an alkali metal or a non-steroid anti-inflammatory analgesic in a free state which is more acidic.
- There is a patch containing the above organic acid Japanese Patent Publication No. 7-47553, but these inventions relate to acidic drugs and not to basic drugs.
- WO 96/16642 also discloses a patch preparation technique in which an organic acid salt is added to a salt-type basic drug. There was no indication of increasing the solubility of the basic drug salt in liquid components ranging from 13 (cal I cm 3 ) 1/2 . That is, in the inventions so far, basic drugs are dissolved in the form of a salt, particularly in a transdermal formulation containing a liquid component, and a transdermal formulation that obtains the expected transdermal absorption of the drug is disclosed. It was a problem that could not be solved at all. Disclosure of the invention
- the present invention has been made to solve the above-mentioned problems of the prior art, and dissolves a basic drug or a salt thereof in a liquid component, enhances the transdermal absorbability of the drug, and provides a skin as an application site. It is intended to provide a transdermal preparation that is safe for patients.
- FIG. 1 shows the solubility of various liquid components when oxyptinin hydrochloride was used as the basic drug salt.
- the white bar graph in the figure shows the case where the organic acid salt was not added, and the black bar graph shows the case where the organic acid salt of the present invention was added.
- FIG. 2 shows the solubility of various liquid components when fentanyl quenate is used as the basic drug salt.
- the white bar graph in the figure shows the case where the organic acid salt was not added, and the black bar graph shows the case where the organic acid salt of the present invention was added.
- FIG. 3 shows the solubility of various liquid components when ketotifen fumarate is used as a basic drug salt.
- the white bar graph in the figure indicates the case where the organic acid salt was not added, and the black bar graph indicates the case where the organic acid salt of the present invention was added.
- FIG. 4 shows the case where tizanidine hydrochloride was used as the basic drug salt. It shows the solubility for various liquid components when it is present.
- the white bar graph in the figure shows the case where the organic acid salt was not added, and the black bar graph shows the case where the organic acid salt of the present invention was added.
- FIG. 5 shows the solubility of various liquid components when dicardivine hydrochloride was used as the basic drug salt.
- the white bar graph in the figure shows the case where the organic acid salt was not added, and the black bar graph shows the case where the organic acid salt of the present invention was added.
- the value is 1 3 (c al I cm 3 ) 1/2 or more liquid components of the solubility parameter
- Comparative Examples Comparative Example 5 - D, Comparative Example 5 - F
- FIG. 6 is a graph showing the skin permeability of a patch using various organic acid salts when tizanidine hydrochloride is used as a basic drug salt.
- the black circles in the figure indicate the case where sodium acetate was used as the organic acid salt (Example 6—A), and the black squares indicate the case where sodium propionate was used as the organic acid salt.
- Case (Example 6 — B) the black triangle indicates the case where sodium hydroxide was used as the organic acid salt (Example 6 — C), and the black diamond indicates the organic acid salt.
- Example 6—D when sodium benzoate is used, and the white circle shows the case where no organic acid salt is used as a comparative example (Comparative Example 6).
- Fig. 7 shows the patch using sodium acetate when fentanyl quenchate is used as the basic drug salt and the case where fentanyl is used as the basic drug (integrated with fluorine).
- 5 is a graph showing the skin permeability of a patch using acetic acid.
- the black circles in the figure indicate the case of using sodium acetate using phenyl phenyl citrate (Example 7-A), and the white circles indicate the cases where sodium acetate was not used. This is shown as an example (Comparative Example 7—A).
- the black squares in the figure indicate the cases where acetic acid using fentanyl was used (Example 7-B), and the white squares indicate the cases where acetic acid was not used (Comparative Example 7-B). ).
- FIG. 8 shows sodium acetate when oxyptinin hydrochloride was used as the basic drug salt.
- FIG. 9 is a graph showing the skin permeability of a patch using acetic acid as a patch using lithium and as a basic drug (free form) using oxyptinin.
- FIG. The black circles in the figure indicate the case of using sodium acetate using oxyptinin hydrochloride (Example 8-A), and the white circles indicate the case of using no sodium acetate for comparison (Comparative Example). 8—A).
- the present invention relates to a basic drug or a salt thereof, an organic acid or a salt thereof, and a solubility parameter.
- a basic drug or a salt thereof an organic acid or a salt thereof, and a solubility parameter.
- ⁇ 13 (cal Icm 3 ) By combining liquid components in the range of 1/2 , or the value of basic drug (free form), organic acid (free form) and solubility parameter But? It is intended to provide a transdermal preparation containing a liquid component in the range of 1 to 13 (cal / cm 3 ) 1/2 .
- the transdermal preparation of the present invention is preferably a patch, and more preferably a non-aqueous patch substantially containing no water.
- the composition and form of the transdermal preparation of the present invention will be described.
- Basic drug salts that increase the solubility in liquid components in the range of 1/2 are not particularly limited, but include, for example, hypnotic sedatives ( Flurazebam hydrochloride, rilmazafone hydrochloride, etc.), antipyretic and anti-inflammatory analgesics (butorphanol tartrate, perisoxal citrate, etc.), excitement stimulants (methane phthalamine hydrochloride, methyl phenylidene hydrochloride, etc.), agents for psychiatric nerves (chlorpromazine hydrochloride, hydrochloric acid) Imimiramin, fluvoxamine maleate, sertraline hydrochloride, etc., local anesthetics (lidocaine hydrochloride, procaine hydrochloride, etc.), drugs for urinary organ
- the solubility in liquid components whose solubility parameter is in the range of 7 to 13 (cal I cm 3 ) 1/2 is increased by organic acids or inorganic acids.
- the type of the basic drug is not particularly limited, and examples thereof include the above-mentioned drugs.
- these drugs may be used alone or in combination of two or more, and naturally include drugs in any form of inorganic salts or organic salts.
- the amount of these drugs depends on the type of drug, but is about 0.1 to 50% by weight based on the total weight of the transdermal preparation.
- the drug when the transdermal preparation of the present invention is a patch, the drug has the entire composition of the adhesive layer in consideration of a sufficient amount of permeation as the patch and irritation to the skin such as redness. It is preferably present in an amount of 0.1 to 20% by weight, based on the weight of the composition.
- the organic acid or salt thereof used in the transdermal preparation of the present invention includes aliphatic (mono, di, tri) carboxylic acid (for example, carboxylic acid, propionic acid, isobutyric acid, caproic acid) , Cabrylic acid, lactic acid, maleic acid, birubic acid, oxalic acid, succinic acid, tartaric acid, lingic acid, etc.), aromatic carboxylic acids (eg, phthalic acid, salicylic acid, benzoic acid, acetylsalicylic acid, etc.), Alkyl sulfonic acid (for example, ethanesulfonic acid, propyl sulfonic acid, butanesulfonic acid, polyoxyethylene alkyl ether sulfonic acid, etc.), alkyl sulfonic acid derivative (for example, N-2-hydroxyhydroxyethyl N, 1-2) —Ethanesulfonic acid (hereinafter abbreviated as “HEPES”)
- organic acids or salts thereof are suitable for percutaneous absorption preparations (when the percutaneous absorption preparation is a patch) in consideration of sufficient permeation amount as a percutaneous absorption preparation and irritation to skin. Is preferably from 0.01 to 20% by weight, more preferably from 0.1 to 15% by weight, particularly preferably from 0 to 20% by weight, based on the total weight of the composition of the adhesive layer). It can be present in an amount of 1 to 10% by weight.
- the mixing ratio between the basic drug salt and the organic acid salt or the mixing ratio between the basic drug and the organic acid is preferably 5/1 to 1/5 (molar ratio).
- the lipophilic index a is the solubility parameter of (5 values?
- solubility parameter 5 8.1
- isoprovir myristate 8.5
- kuroyu miton 9.9
- triacetin 10.2
- oleic acid 7.7
- triethyl citrate 11.5)
- propylene glycol 12.6)
- Such liquid components can be incorporated in total amounts of 3.0 to 70% by weight.
- the adhesive layer of the transdermal preparation of the present invention may contain an absorption enhancer.
- the absorption enhancer that can be used include compounds that have been conventionally recognized as having an effect of promoting absorption on the skin. Any of them may be used.
- fatty acids having 6 to 20 carbon chains fatty alcohols, fatty acid esters or ethers, aromatic organic acids, aromatic alcohols, aromatic organic acid esters or ethers (the above are saturated or unsaturated) Any of saturated and cyclic or linear branched), lactic acid esters, acetic acid esters, monoterpene compounds, sesquiterpene compounds, Azone, Azone (A zone) derivatives, glycerin fatty acid esters, sorbitan fatty acid esters (Span type) Polysorbate type (Tween type), polyethylene glycol Lumpur fatty acid esters, polyoxyethylene hardened castor oils (H C O system), sucrose fatty acid esters.
- the absorption enhancer that can be used include compounds that have been conventionally recognized as having an
- Such an absorption enhancer is used in consideration of sufficient permeability as a percutaneous absorption preparation and skin irritation such as redness and edema, etc. Is preferably 0.1 to 20% by weight, more preferably 0.05 to 10% by weight, based on the total weight of the composition of the adhesive layer in the case of a patch. Particularly preferably, it can be incorporated in an amount of 0.1 to 5% by weight.
- the transdermal preparation of the present invention is preferably a patch preparation.
- a patch preparation it is particularly preferably a non-aqueous transdermal preparation containing no water.
- plasticizer for the adhesive layer in the case of a patch preparation petroleum-based oil (for example, varaffine-based process oil, naphthene-based process oil, aromatic-based process oil, etc.), squalane, squalene, or vegetable-based oil (for example Olive oil, camellia oil, castor oil, tall oil, laccase oil, silicon oil, dibasic acid ester (eg, dibutyl phthalate, octyl phthalate, etc.), liquid rubber (eg, polybutene) , Liquid isoprene rubber), diethylene glycol, polyethylene glycol, glycol salicylate, propylene glycol, dibrovirene glycol, triacetin, triethyl citrate, crotamiton, getyl sebacate and the like.
- petroleum-based oil for example, varaffine-based process oil, naphthene-based process oil, aromatic-based process oil, etc.
- squalane for example Olive oil, camellia oil
- liquid paraffin particularly preferred are liquid paraffin, liquid polybutene, glycol salicylate, crotamiton, and getyl sebacate.
- Two or more of these components may be used as a mixture, and the amount of such a plasticizer based on the entire composition of the adhesive layer is sufficient to maintain sufficient permeability and sufficient cohesive strength as a patch preparation.
- the total amount can be 5 to 70% by weight, preferably 5 to 60% by weight, and more preferably 5 to 50% by weight.
- styrene-isoprene-styrene block copolymer hereinafter abbreviated as SIS
- isoprene rubber Polyisobutylene (hereinafter abbreviated as PIB)
- PIB styrene-butadiene-styrene block copolymer
- SBS styrene-butadiene rubber
- SBR styrene-butadiene rubber
- acryl-based Mention may be made of polymers (at least two copolymers of 2-ethylhexyl acrylate, vinyl acetate, methacrylate, methoxyl acrylate, acrylic acid). Particularly, SIS, PIB or two kinds of blend and acrylic polymers are preferred.
- the amount of the hydrophobic polymer based on the total weight of the composition of the pressure-sensitive adhesive layer is preferably 5 to 60% by weight for SIS, PIB, etc. in consideration of formation of the pressure-sensitive adhesive layer and sufficient permeability.
- it can be in an amount of from 10 to 50% by weight, more preferably from 15 to 40% by weight.
- an acrylic polymer it can be in an amount of 10 to 98% by weight, preferably 20 to 98% by weight, and more preferably 30 to 98% by weight.
- tackifying resin used in the adhesive layer of the patch preparation examples include rosin derivatives (for example, rosin, glycerin ester of rosin, hydrogenated rosin, glycerin ester of hydrogenated rosin, rosin Phenol ester, etc.), alicyclic saturated hydrocarbon resin, aliphatic hydrocarbon resin, terpene resin, maleic resin and the like.
- rosin derivatives for example, rosin, glycerin ester of rosin, hydrogenated rosin, glycerin ester of hydrogenated rosin, rosin Phenol ester, etc.
- alicyclic saturated hydrocarbon resin aliphatic hydrocarbon resin
- terpene resin maleic resin and the like.
- hydrogenated rosin glycerin esters, alicyclic saturated hydrocarbon resins, aliphatic hydrocarbon resins, and terpene resins are preferred.
- the amount of the tackifying resin based on the entire composition of the pressure-sensitive adhesive layer is 10 to 70% by weight in consideration of sufficient adhesive force as a patch and irritation to the skin at the time of peeling. It can preferably be 15 to 60% by weight, more preferably 20 to 50% by weight.
- antioxidants include tocopherol and their ester derivatives, ascorbic acid, stearic acid ascorbate, nordihydroxyadialetic acid, dibutylhydroxytoluene (BHT), and butylhydroxydiazo.
- BHT dibutylhydroxytoluene
- fillers include calcium carbonate, magnesium carbonate, silicates (eg, aluminum silicate, magnesium silicate, etc.), citric acid, barium sulfate, calcium sulfate, calcium zincate, zinc oxide, titanium oxide, etc. Is desirable.
- crosslinking agent examples include thermosetting resins such as amino resin, phenol resin, epoxy resin, alkyd resin, and unsaturated polyester, isocyanate compound, block isocyanate compound, organic crosslinking agent, and the like.
- An inorganic crosslinking agent such as a metal or a metal compound is desirable.
- preservatives ethyl ethyl paraoxybenzoate, provyl paraoxybenzoate, butyl paraoxybenzoate and the like are desirable.
- UV absorbers include p-aminobenzoic acid derivatives, anthranilic acid derivatives, salicylic acid derivatives, coumarin derivatives, amino acid compounds, imidazoline derivatives, bilimidine derivatives, and dioxane derivatives. Desirable.
- Such antioxidants, fillers, cross-linking agents, preservatives, and UV absorbers are preferably at most 10% by weight, more preferably at most 10% by weight, based on the total weight of the composition of the adhesive layer of the patch preparation. It can be present in an amount of preferably 5% by weight or less, particularly preferably 2% by weight or less.
- the adhesive layer having such a composition can be produced by any method.
- a base composition containing a drug is melted by heat, coated on a release paper or a support, and then adhered to the release paper or the support to obtain the present preparation.
- the base component containing the drug is dissolved in a solvent such as toluene, hexane, or ethyl acetate, spread on release paper or a support, and the solvent is dried and removed.
- the adhesive layer has the above-mentioned composition containing an organic acid or a salt thereof and a drug
- the other components and the material of each component are as follows: May be used.
- These patch preparations can be composed of the adhesive layer, a support layer for supporting the adhesive layer, and a release paper layer provided on the adhesive layer.
- a stretchable or non-stretchable support can be used.
- cloth It is selected from nonwoven fabric, polyurethane, polyester, polyvinyl acetate, polyvinylidene chloride, polyethylene, polyethylene terephthalate, aluminum sheet, etc., or a composite material thereof.
- the transdermal preparation of the present invention comprises a basic drug or a salt thereof, an organic acid or a salt thereof, and a liquid having a solubility parameter value of 7 to 13 (cal / cm 3 ) 1/2.
- the other components and the materials of each component may be of any kind.However, in order to dissolve the basic drug or its salt in the base component. If the pulverization, stirring or heating step is performed together with an organic acid or a salt thereof, the effect can be more effectively obtained.
- the percutaneous absorption-type preparation of the present invention is excellent in skin permeability, skin irritation, content stability of a drug, or physical stability of a base.
- Liquid components liquid paraffin, isoprovir myristate, crotamiton, triacetin, oleic acid, oleyl alcohol, triethyl citrate, silicone, propylene glycol, bilotiodecane, ethylene glycol, water
- the solubility of the basic drug salt in was measured.
- Liquid components such as liquid paraffin (Example 11-A), isopropyl myristate (Example 1-B), crotamiton (Example 11-C), and triacetin (Example 11-A)
- Example 11-H silicon oil
- 10 g of sodium acetate, 0.1 g of sodium acetate and an excess amount of oxyptinin hydrochloride are placed in a mortar, mixed well for 30 minutes, transferred to a vial, and stirred at room temperature for 12 hours. This was filtered with a filter, and the concentration of oxyptinin hydrochloride in the filtrate was measured.
- Figure 1 shows the results. Comparative Example 1
- Liquid paraffin which is a liquid component (Comparative Example 1-1A), isopropyl myristate (Comparative Example 1-1B), crotamiton (Comparative Example 1-C), and triacetin (Comparative Example 1-1D) Oleic acid (Comparative Example 1-1E), oleyl alcohol (Comparative Example 1-1F), triethyl citrate (Comparative Example 1-1G), and silicone oil (Comparative Example 1-1H).
- Add an excess amount of oxypeptinine hydrochloride to 10 g in a mortar, mix well for 30 minutes, transfer to a vial, and stir at room temperature for 12 hours. This was filtered through a filter, and the concentration of oxyptinin hydrochloride in the filtrate was measured.
- Fig. 1 shows the results.
- Example 2 shows the results.
- Liquid components such as liquid paraffin (Example 2-A), isopropyl myristate (Example 2-B), crotamiton (Example 2-C), triacetin (Example 2-D), Oleic acid (Example 2-E), oleyl alcohol (Example 2-F), triethyl citrate (Example 2-G), and silicone oil (Example 2-H) were used. Then, 10 g of sodium acetate, 0.1 lg of sodium acetate and an excess amount of phantanyl citrate are placed in a mortar, mixed well for 30 minutes, transferred to a vial, and stirred at room temperature for 12 hours. This was filtered through a filter, and the concentration of phentanyl citrate in the filtrate was measured. Figure 2 shows the results. Comparative Example 2
- Liquid components such as liquid paraffin (Comparative Example 2-A), isopropyl myristate (Comparative Example 2-B), crotamiton (Comparative Example 2-C), triacetin (Comparative Example 2-D), Oleic acid (Comparative Example 2-E), oleyl alcohol (Comparative Example 2-F), triethyl citrate (Comparative Example 2-G), and silicon oil (Comparative Example 2-H) were prepared.
- An excess amount of phantanyl citrate per 10 g is placed in a mortar, mixed well for 30 minutes, then transferred to a vial and stirred at room temperature for 12 hours. This was filtered through a filter, and the concentration of phenanyl citrate in the filtrate was measured. The results are shown in FIG. Example 3
- Liquid components such as liquid paraffin (Example 3-A), isopropyl myristate (Example 3-B), crotamiton (Example 3-C), and triacetin (Example 3-D) ), Oleic acid (Example 3-E), oleyl alcohol (Example 3-F), triethyl citrate (Example 3-G), and silicon oil (Example 3-H).
- Example 3-A Liquid components such as liquid paraffin (Example 3-A), isopropyl myristate (Example 3-B), crotamiton (Example 3-C), and triacetin (Example 3-D) ), Oleic acid (Example 3-E), oleyl alcohol (Example 3-F), triethyl citrate (Example 3-G), and silicon oil (Example 3-H).
- Liquid components such as liquid paraffin (Comparative Example 3-A), isoprovir myristate (Comparative Example 3-B), crotamiton (Comparative Example 3-C), triacetin (Comparative Example 3-D), Oleic acid (Comparative Example 3-E), oleyl alcohol (Comparative Example 3-F), triethyl citrate (Comparative Example 3-G), and silicon oil (Comparative Example 3-H) were respectively used.
- An excess amount of ketothiophene fumarate with respect to 10 g is placed in a mortar, mixed well for 30 minutes, then transferred to a vial and stirred at room temperature for 12 hours. This was filtered through a filter, and the concentration of ketotifen fumarate in the filtrate was measured. The results are shown in FIG. Example 4
- Liquid paraffin which is a liquid component (Example 41-A), isopropyl myristate (Example 41-B), crotamiton (Example 4-C), triacetin (Example 41-D) Oleic acid (Example 4-E), oleyl alcohol (Example 41-F), triethyl citrate (Example 41-G), and silicone oil (Example 41-H), respectively.
- Figure 4 shows the results. Comparative Example 4
- Liquid ingredients such as liquid paraffin (Example 5—A), pyrothiodecane (Example 5—B), and propylene glycol (Example 5—C) were each 10 g, sodium acetate 0. Take 1 g and an excess amount of dicardivine hydrochloride in a mortar, mix well for 30 minutes, transfer to a vial, and stir at room temperature for 12 hours. This was filtered through a filter, and the concentration of dicardivine hydrochloride in the filtrate was measured. The results are shown in FIG. Comparative Example 5
- Example 6 A to 6 — D and Comparative Example 6
- Example 8 — A, 8 — B and Comparative Example Apply the preparations obtained in 8-A and 8-B, and use saline for the receptor layer at a rate of 5 ml / hr (hr) every 2 hours 18 hours or 1 hour Sampling was performed for up to 9 hours.
- Example 7 A liquid paraffin was 32.0% without using an organic acid salt, and the other components and the trial production process were the same as in Example 6-A.
- Example 7-B The liquid paraffin was 31.5% without using an organic acid salt, and the other components and the trial production process were the same as in Example 7-A.
- Example 7-B Example 7-B
- Example 8 A first organic component was not used, the liquid paraffin was 32.9%, and the other components and the trial production process were the same as in Example 7-B.
- Example 8 B SIS 26.0% hydrogenated rosin ester 38.0%
- the drug can be efficiently absorbed into the circulating blood via the skin. It also avoids the digestive system side effects that occur with oral administration and the central side effects that can occur with rapid increases in blood levels. Furthermore, it is extremely irritating to the skin, and is particularly effective as an external preparation for transdermal application.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT00915409T ATE485815T1 (de) | 1999-04-13 | 2000-04-07 | Zubereitungen zur perkutanen absorption |
US09/958,624 US7504114B1 (en) | 1999-04-13 | 2000-04-07 | Preparations for percutaneous absorption |
CA002369012A CA2369012A1 (en) | 1999-04-13 | 2000-04-07 | Preparations for percutaneous absorption |
JP2000610453A JP4643018B2 (ja) | 1999-04-13 | 2000-04-07 | 経皮吸収型製剤 |
EP00915409A EP1170004B1 (en) | 1999-04-13 | 2000-04-07 | Preparations for percutaneous absorption |
DE60045153T DE60045153D1 (de) | 1999-04-13 | 2000-04-07 | Zubereitungen zur perkutanen absorption |
AU36732/00A AU778011B2 (en) | 1999-04-13 | 2000-04-07 | Preparations for percutaneous absorption |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11/104828 | 1999-04-13 | ||
JP10482899 | 1999-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000061120A1 true WO2000061120A1 (fr) | 2000-10-19 |
Family
ID=14391254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2000/002266 WO2000061120A1 (fr) | 1999-04-13 | 2000-04-07 | Préparations destinées à être absorbées par voie percutanée |
Country Status (10)
Country | Link |
---|---|
US (1) | US7504114B1 (ja) |
EP (1) | EP1170004B1 (ja) |
JP (1) | JP4643018B2 (ja) |
KR (1) | KR100674108B1 (ja) |
CN (1) | CN1159002C (ja) |
AT (1) | ATE485815T1 (ja) |
AU (1) | AU778011B2 (ja) |
CA (1) | CA2369012A1 (ja) |
DE (1) | DE60045153D1 (ja) |
WO (1) | WO2000061120A1 (ja) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004067539A (ja) * | 2002-08-02 | 2004-03-04 | Hisamitsu Pharmaceut Co Inc | 経皮投与用貼付剤 |
WO2005049004A1 (ja) * | 2003-11-21 | 2005-06-02 | Sekisui Chemical Co.,Ltd. | 貼付剤 |
WO2005115355A1 (ja) * | 2004-05-28 | 2005-12-08 | Hisamitsu Pharmaceutical Co., Inc. | 貼付製剤 |
WO2005117886A1 (ja) * | 2004-06-01 | 2005-12-15 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
JP2006169238A (ja) * | 2004-11-22 | 2006-06-29 | Hisamitsu Pharmaceut Co Inc | 薬物含有貼付剤 |
WO2006080199A1 (ja) * | 2005-01-31 | 2006-08-03 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
JP2006312586A (ja) * | 2003-11-21 | 2006-11-16 | Sekisui Chem Co Ltd | 貼付剤 |
WO2009066457A1 (ja) | 2007-11-22 | 2009-05-28 | Medrx Co., Ltd. | 脂肪酸系イオン液体を有効成分とする外用剤組成物 |
WO2009096354A1 (ja) * | 2008-01-28 | 2009-08-06 | Teikoku Seiyaku Co., Ltd. | フェンタニル含有外用貼付剤 |
WO2009110351A1 (ja) * | 2008-03-03 | 2009-09-11 | 久光製薬株式会社 | 経皮吸収製剤 |
JP2009242303A (ja) * | 2008-03-31 | 2009-10-22 | Sekisui Medical Co Ltd | 貼付剤 |
WO2009157586A1 (ja) * | 2008-06-27 | 2009-12-30 | 祐徳薬品工業株式会社 | フェンタニルまたはその塩含有経皮吸収型貼付剤 |
JP2010006762A (ja) * | 2008-06-27 | 2010-01-14 | Yutoku Yakuhin Kogyo Kk | 安定化されたフェンタニルまたはその塩含有組成物及びこれを用いた医薬製剤並びにフェンタニルまたはその塩の安定化方法 |
JPWO2008026381A1 (ja) * | 2006-08-28 | 2010-01-14 | 久光製薬株式会社 | 爪用貼付剤 |
US7744918B2 (en) | 2004-11-22 | 2010-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Drug-containing patch |
WO2010083035A2 (en) * | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
WO2011074567A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
US8273405B2 (en) | 2001-05-01 | 2012-09-25 | A.V. Topcheiv Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
WO2012144405A1 (ja) | 2011-04-18 | 2012-10-26 | 久光製薬株式会社 | 貼付剤の製造方法及び貼付剤 |
WO2013081014A1 (ja) * | 2011-11-28 | 2013-06-06 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
US8481071B2 (en) | 2001-05-01 | 2013-07-09 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US8481059B2 (en) | 2001-05-01 | 2013-07-09 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel compositions |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
WO2013140799A1 (ja) * | 2012-03-22 | 2013-09-26 | 杏林製薬株式会社 | 経皮吸収型製剤 |
WO2014017593A1 (ja) * | 2012-07-26 | 2014-01-30 | 久光製薬株式会社 | 貼付剤及びその製造方法 |
US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
US8821901B2 (en) | 2001-05-01 | 2014-09-02 | A.V. Topchiev Institute Of Petrochemical Synthesis Russian Academy Of Sciences | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
JP2014172885A (ja) * | 2013-03-11 | 2014-09-22 | Nitto Denko Corp | 経皮吸収促進用組成物および貼付製剤 |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
WO2014174564A1 (ja) * | 2013-04-22 | 2014-10-30 | 祐徳薬品工業株式会社 | メマンチン含有経皮吸収型貼付製剤 |
WO2015025766A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
USRE45666E1 (en) | 2000-07-07 | 2015-09-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
JP2015214505A (ja) * | 2014-05-09 | 2015-12-03 | 救急薬品工業株式会社 | フェンタニル含有貼付剤 |
JP2016179949A (ja) * | 2015-03-23 | 2016-10-13 | 救急薬品工業株式会社 | 塩基性薬物塩含有経皮投与テープ剤の製造方法 |
WO2018104772A1 (ja) * | 2016-12-05 | 2018-06-14 | 王子ホールディングス株式会社 | 経皮吸収型製剤 |
US10493156B2 (en) | 2012-07-26 | 2019-12-03 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for producing the same |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
RU2708563C2 (ru) * | 2001-03-16 | 2019-12-10 | Алза Корпорейшн | Трансдермальный пластырь для введения фентанила |
US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
ES2307955T3 (es) * | 2002-03-06 | 2008-12-01 | Hexal Ag | Sistema transdermico con fentanil. |
WO2005011683A1 (ja) * | 2003-08-04 | 2005-02-10 | Kyorin Pharmaceutical Co., Ltd. | 経皮吸収型製剤 |
US8080560B2 (en) * | 2004-12-17 | 2011-12-20 | 3M Innovative Properties Company | Immune response modifier formulations containing oleic acid and methods |
WO2006082888A1 (ja) * | 2005-02-03 | 2006-08-10 | Kyorin Pharmaceutical Co., Ltd. | 経皮吸収型製剤 |
US9283177B2 (en) * | 2007-01-16 | 2016-03-15 | Juventio, Llc | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
WO2008089242A1 (en) * | 2007-01-16 | 2008-07-24 | Dermworx, Incorporated | Topical anesthetic for rapid local anesthesia and method of applying a topical anesthetic |
KR101500022B1 (ko) * | 2007-06-21 | 2015-03-06 | 가부시키가이샤 후지모토 코포레이션 | 경피 또는 경점막 투여용 조성물 |
RU2499583C2 (ru) * | 2007-10-15 | 2013-11-27 | Алза Корпорейшн | Заместительное трансдермальное введение фентанила один раз в день |
CA2730787A1 (en) * | 2008-07-16 | 2010-01-21 | David M. Cohen | Topical drug delivery system |
TWI448309B (zh) * | 2009-01-26 | 2014-08-11 | Teikoku Seiyaku Kk | 含吩坦尼(fentanyl)之外用貼附劑 |
KR20120107153A (ko) * | 2011-03-15 | 2012-10-02 | 아이큐어 주식회사 | 펜타닐 경피 패치제 |
EP2921184A1 (de) * | 2014-03-19 | 2015-09-23 | LTS LOHMANN Therapie-Systeme AG | Überpflaster mit verbesserter Verträglichkeit und einer langen Haftungsdauer und Verfahren zu seiner Herstellung |
CN107427582B (zh) | 2015-04-30 | 2021-03-05 | 久光制药株式会社 | 多汗症治疗用外用剂 |
US20190046493A1 (en) * | 2016-02-25 | 2019-02-14 | Hisamitsu Pharmaceutical Co., Inc. | Liquid external preparation |
US11033511B2 (en) * | 2017-08-01 | 2021-06-15 | Hisamitsu Pharmaceutical Co., Inc. | Pharmaceutical patch |
WO2024020549A1 (en) * | 2022-07-21 | 2024-01-25 | Integurx Therapeutics, Ll | Transdermal anticoagulant compositions |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05946A (ja) * | 1991-06-27 | 1993-01-08 | Nichiban Co Ltd | ケトチフエン含有経皮吸収製剤 |
EP0580074A1 (en) * | 1992-07-20 | 1994-01-26 | ASTA Medica Aktiengesellschaft | Stable preparation containing azelastine hydrochloride |
JPH0640947A (ja) * | 1992-07-28 | 1994-02-15 | T T S Gijutsu Kenkyusho:Kk | 経皮吸収製剤用組成物および経皮吸収製剤 |
WO1996016642A1 (fr) * | 1994-11-29 | 1996-06-06 | Hisamitsu Pharmaceutical Co., Inc. | Composition de timbre transdermique du type matriciel |
JPH09208464A (ja) * | 1996-02-07 | 1997-08-12 | Takeda Chem Ind Ltd | 抗真菌性外用組成物 |
WO1997042952A1 (fr) * | 1996-05-13 | 1997-11-20 | Hisamitsu Pharmaceutical Co., Inc. | Preparation en ruban percutanee contenant du fentanyl |
JPH10204001A (ja) * | 1996-11-15 | 1998-08-04 | Kao Corp | 経皮吸収促進剤 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3472931A (en) | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
US4017641A (en) | 1975-01-31 | 1977-04-12 | The Procter & Gamble Company | Skin moisturizing compositions containing 2-pyrrolidinone |
JPS5661312A (en) | 1979-10-24 | 1981-05-26 | Nichiban Co Ltd | Pressure-sensitive adhesive sheet for remedying skin disease |
CA1248450A (en) * | 1984-04-05 | 1989-01-10 | Kazuo Kigasawa | Soft patch |
JPS60224638A (ja) * | 1984-04-23 | 1985-11-09 | Kao Corp | 経皮吸収促進剤およびこれを含有する外用剤 |
JPS61249934A (ja) | 1985-04-27 | 1986-11-07 | Nitto Electric Ind Co Ltd | 外皮投与用組成物 |
JPH0747535B2 (ja) | 1985-11-26 | 1995-05-24 | 日東電工株式会社 | 消炎鎮痛用貼付剤 |
JPS62181226A (ja) | 1986-02-05 | 1987-08-08 | Ikeda Mohandou:Kk | 消炎鎮痛外用剤 |
GR871267B (en) * | 1986-08-18 | 1987-12-24 | Chugai Pharmaceutical Co Ltd | Method for the manufacture of a pharmaceutical preparation for administration by percutaneous absortion |
JPS6379820A (ja) | 1986-09-22 | 1988-04-09 | Nitto Electric Ind Co Ltd | 経皮投与用医薬製剤 |
JPS63159315A (ja) | 1986-12-22 | 1988-07-02 | Yuutoku Yakuhin Kogyo Kk | パツプ剤 |
JP3053913B2 (ja) | 1991-07-15 | 2000-06-19 | 帝三製薬株式会社 | ビンポセチン類含有貼付剤 |
JP3786684B2 (ja) * | 1992-05-13 | 2006-06-14 | アルザ・コーポレーション | オキシブチニンの経皮投与 |
US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
US6203817B1 (en) * | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
JP4205778B2 (ja) * | 1998-04-17 | 2009-01-07 | 久光製薬株式会社 | 貼付製剤 |
-
2000
- 2000-04-07 KR KR1020017011653A patent/KR100674108B1/ko active IP Right Grant
- 2000-04-07 WO PCT/JP2000/002266 patent/WO2000061120A1/ja active IP Right Grant
- 2000-04-07 CA CA002369012A patent/CA2369012A1/en not_active Abandoned
- 2000-04-07 DE DE60045153T patent/DE60045153D1/de not_active Expired - Lifetime
- 2000-04-07 JP JP2000610453A patent/JP4643018B2/ja not_active Expired - Lifetime
- 2000-04-07 EP EP00915409A patent/EP1170004B1/en not_active Expired - Lifetime
- 2000-04-07 AT AT00915409T patent/ATE485815T1/de not_active IP Right Cessation
- 2000-04-07 US US09/958,624 patent/US7504114B1/en not_active Expired - Fee Related
- 2000-04-07 CN CNB008061483A patent/CN1159002C/zh not_active Expired - Lifetime
- 2000-04-07 AU AU36732/00A patent/AU778011B2/en not_active Ceased
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05946A (ja) * | 1991-06-27 | 1993-01-08 | Nichiban Co Ltd | ケトチフエン含有経皮吸収製剤 |
EP0580074A1 (en) * | 1992-07-20 | 1994-01-26 | ASTA Medica Aktiengesellschaft | Stable preparation containing azelastine hydrochloride |
JPH0640947A (ja) * | 1992-07-28 | 1994-02-15 | T T S Gijutsu Kenkyusho:Kk | 経皮吸収製剤用組成物および経皮吸収製剤 |
WO1996016642A1 (fr) * | 1994-11-29 | 1996-06-06 | Hisamitsu Pharmaceutical Co., Inc. | Composition de timbre transdermique du type matriciel |
JPH09208464A (ja) * | 1996-02-07 | 1997-08-12 | Takeda Chem Ind Ltd | 抗真菌性外用組成物 |
WO1997042952A1 (fr) * | 1996-05-13 | 1997-11-20 | Hisamitsu Pharmaceutical Co., Inc. | Preparation en ruban percutanee contenant du fentanyl |
JPH10204001A (ja) * | 1996-11-15 | 1998-08-04 | Kao Corp | 経皮吸収促進剤 |
Non-Patent Citations (1)
Title |
---|
GORUKANTI, S. R.: "Transdermal delivery of antiparkinsonian agent, benztropine I . Effect of vehicles on skin permeation", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 192, no. 2, November 1999 (1999-11-01), pages 159 - 172, XP002929113 * |
Cited By (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE45666E1 (en) | 2000-07-07 | 2015-09-08 | A.V. Topchiev Institute Of Petrochemical Synthesis | Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties |
US8481071B2 (en) | 2001-05-01 | 2013-07-09 | Corium International, Inc. | Hydrogel compositions with an erodible backing member |
US8617647B2 (en) | 2001-05-01 | 2013-12-31 | A.V. Topchiev Institutes of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US8728445B2 (en) | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
US8821901B2 (en) | 2001-05-01 | 2014-09-02 | A.V. Topchiev Institute Of Petrochemical Synthesis Russian Academy Of Sciences | Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components |
US8840918B2 (en) | 2001-05-01 | 2014-09-23 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US8541021B2 (en) | 2001-05-01 | 2013-09-24 | A.V. Topchiev Institute Of Petrochemical Synthesis | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US8481059B2 (en) | 2001-05-01 | 2013-07-09 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel compositions |
US8741331B2 (en) | 2001-05-01 | 2014-06-03 | A. V. Topchiev Institute of Petrochemicals Synthesis, Russian Academy of Sciences | Hydrogel compositions with an erodible backing member |
US9084723B2 (en) | 2001-05-01 | 2015-07-21 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions with an erodible backing member |
US10869947B2 (en) | 2001-05-01 | 2020-12-22 | Corium, Inc. | Hydrogel compositions |
US10835454B2 (en) | 2001-05-01 | 2020-11-17 | Corium, Inc. | Hydrogel compositions with an erodible backing member |
US10179096B2 (en) | 2001-05-01 | 2019-01-15 | Corium International, Inc. | Hydrogel compositions for tooth whitening |
US9687428B2 (en) | 2001-05-01 | 2017-06-27 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US9089481B2 (en) | 2001-05-01 | 2015-07-28 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions demonstrating phase separation on contact with aqueous media |
US8273405B2 (en) | 2001-05-01 | 2012-09-25 | A.V. Topcheiv Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US9127140B2 (en) | 2001-05-01 | 2015-09-08 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Water-absorbent adhesive compositions and associated methods of manufacture and use |
US9532935B2 (en) | 2001-05-01 | 2017-01-03 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Hydrogel compositions for tooth whitening |
US9259504B2 (en) | 2001-05-01 | 2016-02-16 | A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences | Non-electrically conductive hydrogel composition |
JP2004067539A (ja) * | 2002-08-02 | 2004-03-04 | Hisamitsu Pharmaceut Co Inc | 経皮投与用貼付剤 |
JP4733416B2 (ja) * | 2003-11-21 | 2011-07-27 | 積水化学工業株式会社 | 貼付剤 |
WO2005049004A1 (ja) * | 2003-11-21 | 2005-06-02 | Sekisui Chemical Co.,Ltd. | 貼付剤 |
JP2006312586A (ja) * | 2003-11-21 | 2006-11-16 | Sekisui Chem Co Ltd | 貼付剤 |
US9144552B2 (en) | 2004-01-30 | 2015-09-29 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Rapidly dissolving film for delivery of an active agent |
US8658201B2 (en) | 2004-01-30 | 2014-02-25 | Corium International, Inc. | Rapidly dissolving film for delivery of an active agent |
WO2005115355A1 (ja) * | 2004-05-28 | 2005-12-08 | Hisamitsu Pharmaceutical Co., Inc. | 貼付製剤 |
JPWO2005115355A1 (ja) * | 2004-05-28 | 2008-03-27 | 久光製薬株式会社 | 貼付製剤 |
JPWO2005117886A1 (ja) * | 2004-06-01 | 2008-04-03 | 久光製薬株式会社 | 貼付剤 |
WO2005117886A1 (ja) * | 2004-06-01 | 2005-12-15 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
US7744918B2 (en) | 2004-11-22 | 2010-06-29 | Hisamitsu Pharmaceutical Co., Inc. | Drug-containing patch |
JP2006169238A (ja) * | 2004-11-22 | 2006-06-29 | Hisamitsu Pharmaceut Co Inc | 薬物含有貼付剤 |
JP5632577B2 (ja) * | 2005-01-31 | 2014-11-26 | 久光製薬株式会社 | 貼付剤 |
WO2006080199A1 (ja) * | 2005-01-31 | 2006-08-03 | Hisamitsu Pharmaceutical Co., Inc. | 貼付剤 |
JPWO2006080199A1 (ja) * | 2005-01-31 | 2008-06-19 | 久光製薬株式会社 | 貼付剤 |
JP2012036198A (ja) * | 2006-08-28 | 2012-02-23 | Hisamitsu Pharmaceut Co Inc | 爪用貼付剤 |
JPWO2008026381A1 (ja) * | 2006-08-28 | 2010-01-14 | 久光製薬株式会社 | 爪用貼付剤 |
JP2011140504A (ja) * | 2006-08-28 | 2011-07-21 | Hisamitsu Pharmaceut Co Inc | 爪用貼付剤 |
US8771726B2 (en) | 2006-08-28 | 2014-07-08 | Hisamitsu Pharmaceutical Co., Inc | Nail patch |
JP4861420B2 (ja) * | 2006-08-28 | 2012-01-25 | 久光製薬株式会社 | 爪用貼付剤 |
JP2010189440A (ja) * | 2006-08-28 | 2010-09-02 | Hisamitsu Pharmaceut Co Inc | 爪用貼付剤 |
EP3011954A1 (en) | 2007-11-22 | 2016-04-27 | Medrx Co., Ltd. | External preparation composition comprising fatty acid-based ionic liquid as active ingredient |
WO2009066457A1 (ja) | 2007-11-22 | 2009-05-28 | Medrx Co., Ltd. | 脂肪酸系イオン液体を有効成分とする外用剤組成物 |
US9517211B2 (en) | 2008-01-28 | 2016-12-13 | Teikoku Seiyaku Co., Ltd. | Fentanyl-containing patch for external use |
JP5431969B2 (ja) * | 2008-01-28 | 2014-03-05 | 帝國製薬株式会社 | フェンタニル含有外用貼付剤 |
WO2009096354A1 (ja) * | 2008-01-28 | 2009-08-06 | Teikoku Seiyaku Co., Ltd. | フェンタニル含有外用貼付剤 |
US10376474B2 (en) | 2008-01-28 | 2019-08-13 | Teikoku Seiyaku Co., Ltd. | Fentanyl-containing patch for external use |
JPWO2009096354A1 (ja) * | 2008-01-28 | 2011-05-26 | 帝國製薬株式会社 | フェンタニル含有外用貼付剤 |
JP5618822B2 (ja) * | 2008-03-03 | 2014-11-05 | 久光製薬株式会社 | 経皮吸収製剤 |
WO2009110351A1 (ja) * | 2008-03-03 | 2009-09-11 | 久光製薬株式会社 | 経皮吸収製剤 |
JP2009242303A (ja) * | 2008-03-31 | 2009-10-22 | Sekisui Medical Co Ltd | 貼付剤 |
WO2009157586A1 (ja) * | 2008-06-27 | 2009-12-30 | 祐徳薬品工業株式会社 | フェンタニルまたはその塩含有経皮吸収型貼付剤 |
JP2010006762A (ja) * | 2008-06-27 | 2010-01-14 | Yutoku Yakuhin Kogyo Kk | 安定化されたフェンタニルまたはその塩含有組成物及びこれを用いた医薬製剤並びにフェンタニルまたはその塩の安定化方法 |
US10238612B2 (en) | 2009-01-14 | 2019-03-26 | Corium International, Inc. | Transdermal administration of tamsulosin |
US8784879B2 (en) | 2009-01-14 | 2014-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
WO2010083035A3 (en) * | 2009-01-14 | 2010-11-04 | Corium International, Inc. | Transdermal administration of tamsulosin |
WO2010083035A2 (en) * | 2009-01-14 | 2010-07-22 | Corium International, Inc. | Transdermal administration of tamsulosin |
US9610253B2 (en) | 2009-01-14 | 2017-04-04 | Corium International, Inc. | Transdermal administration of tamsulosin |
WO2011074567A1 (ja) | 2009-12-15 | 2011-06-23 | 帝國製薬株式会社 | 塩基性消炎鎮痛剤含有経皮吸収製剤 |
JP5698837B2 (ja) * | 2011-04-18 | 2015-04-08 | 久光製薬株式会社 | 貼付剤の製造方法及び貼付剤 |
CN103501770B (zh) * | 2011-04-18 | 2015-04-29 | 久光制药株式会社 | 贴附剂的制造方法及贴附剂 |
WO2012144405A1 (ja) | 2011-04-18 | 2012-10-26 | 久光製薬株式会社 | 貼付剤の製造方法及び貼付剤 |
CN103501770A (zh) * | 2011-04-18 | 2014-01-08 | 久光制药株式会社 | 贴附剂的制造方法及贴附剂 |
WO2013081014A1 (ja) * | 2011-11-28 | 2013-06-06 | 株式会社 ケイ・エム トランスダーム | 貼付剤 |
JPWO2013140799A1 (ja) * | 2012-03-22 | 2015-08-03 | 杏林製薬株式会社 | 経皮吸収型製剤 |
US9457012B2 (en) | 2012-03-22 | 2016-10-04 | Teikoku Seiyaku Co., Ltd. | Transdermal absorption preparation |
WO2013140799A1 (ja) * | 2012-03-22 | 2013-09-26 | 杏林製薬株式会社 | 経皮吸収型製剤 |
US9511051B2 (en) | 2012-07-26 | 2016-12-06 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for producing the same |
WO2014017593A1 (ja) * | 2012-07-26 | 2014-01-30 | 久光製薬株式会社 | 貼付剤及びその製造方法 |
US9687474B2 (en) | 2012-07-26 | 2017-06-27 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
US10814002B2 (en) | 2012-07-26 | 2020-10-27 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for producing the same |
US10583121B2 (en) | 2012-07-26 | 2020-03-10 | Hisamitsu Pharmaceutical Co., Inc. | Patch |
US10080738B2 (en) | 2012-07-26 | 2018-09-25 | Hisamitsu Pharmaceutical Co., Ltd. | Patch and method for producing the same |
US10493156B2 (en) | 2012-07-26 | 2019-12-03 | Hisamitsu Pharmaceutical Co., Inc. | Patch and method for producing the same |
JP2014172885A (ja) * | 2013-03-11 | 2014-09-22 | Nitto Denko Corp | 経皮吸収促進用組成物および貼付製剤 |
WO2014174564A1 (ja) * | 2013-04-22 | 2014-10-30 | 祐徳薬品工業株式会社 | メマンチン含有経皮吸収型貼付製剤 |
WO2015025766A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
JPWO2015025766A1 (ja) * | 2013-08-21 | 2017-03-02 | 久光製薬株式会社 | 貼付剤 |
WO2015025767A1 (ja) * | 2013-08-21 | 2015-02-26 | 久光製薬株式会社 | 貼付剤 |
JP2015214505A (ja) * | 2014-05-09 | 2015-12-03 | 救急薬品工業株式会社 | フェンタニル含有貼付剤 |
JP2016179949A (ja) * | 2015-03-23 | 2016-10-13 | 救急薬品工業株式会社 | 塩基性薬物塩含有経皮投与テープ剤の製造方法 |
JP2018090539A (ja) * | 2016-12-05 | 2018-06-14 | 王子ホールディングス株式会社 | 経皮吸収型製剤 |
WO2018104772A1 (ja) * | 2016-12-05 | 2018-06-14 | 王子ホールディングス株式会社 | 経皮吸収型製剤 |
Also Published As
Publication number | Publication date |
---|---|
US7504114B1 (en) | 2009-03-17 |
CN1346265A (zh) | 2002-04-24 |
AU3673200A (en) | 2000-11-14 |
EP1170004B1 (en) | 2010-10-27 |
CN1159002C (zh) | 2004-07-28 |
ATE485815T1 (de) | 2010-11-15 |
KR100674108B1 (ko) | 2007-01-26 |
KR20010112323A (ko) | 2001-12-20 |
JP4643018B2 (ja) | 2011-03-02 |
EP1170004A1 (en) | 2002-01-09 |
EP1170004A4 (en) | 2004-09-22 |
AU778011B2 (en) | 2004-11-11 |
CA2369012A1 (en) | 2000-10-19 |
DE60045153D1 (de) | 2010-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000061120A1 (fr) | Préparations destinées à être absorbées par voie percutanée | |
KR100385268B1 (ko) | 매트릭스형첩부제제 | |
CA2378385C (en) | Patch formulation for external use including an acid addition salt of a basic drug | |
KR100563906B1 (ko) | 첩부식 제제 | |
US8420117B2 (en) | Patch formulation for external use | |
US7744918B2 (en) | Drug-containing patch | |
US20080038328A1 (en) | Pasting Preparation | |
TW201119691A (en) | Donepazil-containing percutaneous absorption type preparation | |
WO2005102393A1 (ja) | 粘着基剤中の吸収促進剤の含有率を高めた外用貼付剤 | |
EP1847264B1 (en) | Bisoprolol patch | |
JPH1045570A (ja) | フェンタニル含有経皮投与テープ製剤 | |
JP4694967B2 (ja) | 貼付剤 | |
JP5684441B2 (ja) | インドメタシン含有貼付剤 | |
JP4986411B2 (ja) | 貼付剤 | |
JPWO2003013611A1 (ja) | 経皮吸収型製剤 | |
JPWO2017006974A1 (ja) | 経皮吸収型貼付剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 00806148.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR SG US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020017011653 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2000 610453 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2369012 Country of ref document: CA Ref document number: 2369012 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 36732/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09958624 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000915409 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200101098 Country of ref document: VN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017011653 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2000915409 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 36732/00 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020017011653 Country of ref document: KR |